Crinetics Pharmaceuticals (CRNX) Consolidated Net Income (2017 - 2026)

Crinetics Pharmaceuticals' Consolidated Net Income history runs 10 years deep, the most recent figure standing at -$127.7 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 32.25% year-over-year to -$127.7 million; the TTM figure through Mar 2026 stood at -$496.1 million (down 51.23% YoY), while the FY2025 annual figure was -$465.3 million, down 56.18% from the prior year.
• Consolidated Net Income was -$127.7 million for Q1 2026 at Crinetics Pharmaceuticals, down from -$122.6 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$33.6 million in Q1 2022 to a low of -$130.1 million in Q3 2025.
• Historically, Consolidated Net Income has averaged -$74.3 million across 5 years, with a median of -$66.2 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Consolidated Net Income slipped 20.23% in 2023, then plunged 69.33% in 2025.
• A 5-year view of Consolidated Net Income shows it stood at -$45.7 million in 2022, then dropped by 22.53% to -$55.9 million in 2023, then plunged by 44.08% to -$80.6 million in 2024, then sank by 52.16% to -$122.6 million in 2025, then fell by 4.14% to -$127.7 million in 2026.
• The last three Consolidated Net Income figures came in at -$127.7 million (Q1 2026), -$122.6 million (Q4 2025), and -$130.1 million (Q3 2025), per Business Quant data.